Department of Medical Oncology, Yuzuncu Yil University Medical School, Van, Turkey.
Department of Medical Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, Istanbul, Turkey.
J Surg Res. 2019 Sep;241:170-177. doi: 10.1016/j.jss.2019.03.059. Epub 2019 Apr 23.
Possibly originating from interstitial Cajal cells, gastrointestinal stromal tumors (GISTs) have variable biological behaviors. In this study, we aimed to examine the factors affecting the disease-free survival (DFS) in patients with GIST who underwent operation.
The study included the patients who were followed up and treated for GIST in our oncology clinic between 2002 and 2017. The Armed Forces Institute of Pathology criteria (Miettinen risk score) were used for risk stratification of patients.
Seventy-four patients were included to the study, where female patients constituted 52.7%, and the median age was 56 (range: 24-83) y. Most common primary tumor location was the stomach (51.4%), followed by the small intestine (33.8%), colorectum (10.8%), and retroperitoneum (4.1%). Miettinen risk score showed 12 patients (16.7%) at very low risk, 15 patients (20.8%) at low risk, 18 patients (25%) at intermediate risk, and 27 patients (37.5%) at high risk. DFS was significantly lower in patients with small intestine involvement than in cases with stomach involvement (P = 0.004). DFS was significantly lower in patients at high risk than in patients with no high risk (P = 0.034). Small intestine localization (hazard ratio [HR], 8.98; 95% confidence interval [CI], 1.14-8.18), high-risk score (HR, 5.16; 95% CI, 1.42-12.75), c-kit positivity (HR, 0.24; 95% CI, 0.13-0.69), and adjuvant therapy (HR, 0.37; 95% CI, 0.20-0.92) were found to be the most significant factors affecting DFS.
Our study showed negative effects of small intestine localization and high-risk category and positive effects of c-kit positivity and adjuvant therapy on DFS in patients with GIST who underwent operation. When a decision will be made in favor of adjuvant therapy, tumor localization and c-kit mutation should also be considered in addition to risk score.
胃肠道间质瘤(GIST)可能起源于间质 Cajal 细胞,具有不同的生物学行为。本研究旨在探讨接受手术治疗的 GIST 患者无病生存(DFS)的影响因素。
本研究纳入了 2002 年至 2017 年在我院肿瘤科随访和治疗的 GIST 患者。采用武装部队病理研究所(AFIP)标准(Miettinen 风险评分)对患者进行风险分层。
本研究共纳入 74 例患者,其中女性占 52.7%,中位年龄为 56(24-83)岁。最常见的原发肿瘤部位是胃(51.4%),其次是小肠(33.8%)、结直肠(10.8%)和腹膜后(4.1%)。Miettinen 风险评分显示,12 例(16.7%)患者为极低危,15 例(20.8%)为低危,18 例(25%)为中危,27 例(37.5%)为高危。小肠受累患者的 DFS 明显低于胃受累患者(P=0.004)。高危患者的 DFS 明显低于无高危患者(P=0.034)。小肠定位(风险比[HR],8.98;95%置信区间[CI],1.14-8.18)、高危评分(HR,5.16;95%CI,1.42-12.75)、c-kit 阳性(HR,0.24;95%CI,0.13-0.69)和辅助治疗(HR,0.37;95%CI,0.20-0.92)是影响 DFS 的最重要因素。
本研究表明,小肠定位和高危类别对接受手术治疗的 GIST 患者的 DFS 有负面影响,而 c-kit 阳性和辅助治疗有积极影响。在决定是否进行辅助治疗时,除了风险评分外,还应考虑肿瘤定位和 c-kit 突变。